# Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer

> **NCT07177716** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **L & L Bio Co., Ltd., Ningbo, China** · enrollment: 120 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** LB1410
- **BIOLOGICAL:** LB4330
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07177716
- **Lead sponsor:** L & L Bio Co., Ltd., Ningbo, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07177716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07177716, "Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07177716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*